Movano Inc. (NASDAQ:MOVE – Get Free Report) CEO John Mastrototaro sold 33,069 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $20.80, for a total value of $687,835.20. Following the transaction, the chief executive officer directly owned 56,114 shares in the company, valued at $1,167,171.20. This trade represents a 37.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
John Mastrototaro also recently made the following trade(s):
- On Monday, January 5th, John Mastrototaro sold 2,514 shares of Movano stock. The stock was sold at an average price of $8.21, for a total transaction of $20,639.94.
Movano Trading Down 11.0%
NASDAQ MOVE traded down $2.26 on Wednesday, hitting $18.26. 536,287 shares of the stock traded hands, compared to its average volume of 3,181,755. The stock has a 50-day moving average of $9.08 and a 200 day moving average of $7.82. Movano Inc. has a twelve month low of $4.67 and a twelve month high of $55.00. The company has a market capitalization of $15.16 million, a P/E ratio of -1.69 and a beta of 0.79.
Institutional Trading of Movano
An institutional investor recently bought a new position in Movano stock. Citadel Advisors LLC bought a new position in shares of Movano Inc. (NASDAQ:MOVE – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned approximately 5.94% of Movano at the end of the most recent quarter. 16.64% of the stock is currently owned by institutional investors.
Movano News Roundup
Here are the key news stories impacting Movano this week:
- Positive Sentiment: Short interest fell sharply in January (down ~41.4% to 25,442 shares, ~3.4% of the float; days?to?cover ~0.9), reducing one potential source of forced selling and signaling fewer active short positions covering the name — a constructive technical backdrop.
- Positive Sentiment: Technical: a recent note flagged that MOVE cleared its 200?day moving average, which can attract momentum buyers and suggests the stock has regained some longer?term technical support. Article Title
- Neutral Sentiment: Multiple market-wide LULD pauses and trading halts for “MOVE” were recorded yesterday, increasing intraday volatility and temporarily interrupting normal price discovery — these pauses can amplify moves but are procedural, not company?specific.
- Negative Sentiment: Insider selling — CEO John Mastrototaro sold 33,069 shares at an average ~$20.80 (reducing his holding ~37%). Large CEO sales often trigger investor concern about insider conviction and can directly add selling pressure. SEC Filing
- Negative Sentiment: Insider selling — CFO Jeremy Cogan sold 28,736 shares at an average ~$20.78 (reducing his holding ~32%). Combined with the CEO sale, executive exits of this size are likely the primary proximate cause of the down?move as they increase circulating supply and worry some investors. SEC Filing
- Negative Sentiment: Fundamentals remain mixed: last reported quarter (Nov 14) showed an EPS beat on a deeply negative base but revenue materially missed consensus and the company has a tiny market cap and volatile margins — fundamental risk remains high and may amplify selloffs when insiders liquidate.
Analysts Set New Price Targets
Several analysts have issued reports on MOVE shares. Wall Street Zen downgraded shares of Movano from a “hold” rating to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Movano in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.
Get Our Latest Research Report on MOVE
Movano Company Profile
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.
Featured Stories
- Five stocks we like better than Movano
- Your Signature Is Missing – Act Before It’s Too Late
- Buy This Stock at 9:30 AM on MONDAY!
- What Expenses Can Be Deducted From Capital Gains Tax?
- Buy this Gold Stock Before May 2026
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
